Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin

Type1diabetes Clinical Trial

— CLASS15  

Official title:

Alleviating Carbohydrate-Counting Burden in Type 1 Diabetes Using Artificial Pancreas and Sodium Glucose-Linked Transporter 2 Inhibition: A Randomized Open-Label Crossover Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03510000
• Other study ID #: CLASS15
• Status: Completed
• Phase: N/A
• Start date: May 15, 2018
• Est. completion date: November 21, 2019

Study information

• Verified date: June 2021
• Source: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

One of the challenges in the design of the artificial pancreas (AP) is preventing postprandial hyperglycemia. Beyond algorithmic solutions, one countermeasure to postprandial hyperglycemia that may enhance performance of the AP is the use of adjunctive-to-insulin medications such as those in the Sodium Glucose-Linked Transporter 2 inhibitor class. This study evaluates whether use of oral empagliflozin on the background of single-hormone AP can improve postprandial blood glucose control. The investigators will test this hypothesis in a cross-over trial design by comparing open-label empagliflozin versus placebo in the setting of AP on separate study days that involve carbohydrate counting, simple meal announcement and no meal announcement strategies.

Description:

Empagliflozin is a novel anti-diabetic medication and has been approved in Canada. The labelled indication for use of empagliflozin in clinical practice is as an adjunct therapy to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. The investigators are proposing to use the medication as an adjunct anti-diabetic therapy in individuals with type 1 diabetes and would like to examine whether empagliflozin can alleviate need for carb-counting by eliminating post-prandial hyperglycemia in a setting of an artificial pancreas (AP).

The study is designed as a randomized open-label, crossover non-inferiority trial comparing empagliflozin 25 mg oral daily in the setting of the single-hormone AP to single-hormone AP without empagliflozin in adults with type 1 diabetes. The duration of the study for each of the participants is about 3-9 weeks and during this time three different meal announcement strategies for AP will be used, on and off empagliflozin treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: November 21, 2019
• Est. primary completion date: November 21, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Clinical diagnosis of type 1 diabetes for at least one year.

2. Use of insulin pump therapy for at least 3 months.

3. HbA1c = 10%.

4. Women of childbearing potential must agree to use adequate birth control during participation in the study

Exclusion Criteria:

1. Clinically significant nephropathy, neuropathy or retinopathy.

2. Recent acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.

3. History of pheochromocytoma or insulinoma

4. Use of loop diuretics, anticholinergic drugs, beta-blockers at high dose, glucocorticoids (except low stable dose and inhaled steroids), chronic acetaminophen treatment, chronic warfarin treatment

5. Use of non-insulin adjunct anti-hyperglycaemic drug (e.g. metformin, glucagon-like peptide analogues, etc.).

6. Ongoing or planned pregnancy or breastfeeding.

7. Recent severe hypoglycemic episode prior to enrollment

8. Recent diabetic ketoacidosis prior to enrollment

9. Recent history of genital or urinary infection prior to enrollment

10. History of lower limb amputation and recent history of leg or foot infection or wound

11. Anticipating a significant change in exercise regimen between initiations of two intervention blocks (i.e. starting or stopping an organized sport).

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type1diabetes

Intervention

Drug:
• Empagliflozin 25mg
Individuals will test insulin dosing during different meal strategies (carbohydrate counting, plain meal announcement, no meal announcement) in a setting of the single hormone artificial pancreas with or without SGLT2 inhibitor (empagliflozin) addition. After starting the empagliflozin therapy, there will be 1-2 weeks long therapy optimization period and afterwards meal strategies will be administered. Randomization will be used to determine whether participant will start meal strategies on empagliflozin or without empagliflozin, cross-over design enables all participants to undergo all combination of approaches.

Device:
• Single hormone artificial pancreas
Single hormone artificial pancreas will be used as a baseline background intervention standardizing the delivery and dosing of insulin. Artificial pancreas (insulin pump, continuous glucose monitoring device and dosing-suggestion algorithm) will be used by all participants on days when meal strategy intervention will be performed.

Behavioral:
• Meal strategies
Participants will use different approaches (strategies) to insulin dose estimation for ingested carbohydrates on study days. Goal of these various strategies is to recognize magnitude of empagliflozin effect in situations when artificial pancreas algorithm is working with information of different accuracy. Individual meal approach strategies include carbohydrate counting, meal size announcement and no meal announcement. The exception will be combination of no empagliflozin and no meal announcement, which didn't result in sufficient glucose control in previous trials therefore will not be repeated in a current trial. Meal approach strategies will occur on separate days- 5 days in total each day using one meal strategy for all meals during the day.

Locations

Country	Name	City	State
Canada	Institut de recherches cliniques de Montréal	Montréal	Quebec
Canada	McGill University Health Center	Montréal	Quebec
Canada	Sinai Health System	Toronto	Ontario

Sponsors (4)

Lead Sponsor	Collaborator
Samuel Lunenfeld Research Institute, Mount Sinai Hospital	Canadian Diabetes Association, Institut de Recherches Cliniques de Montreal, McGill University Health Centre/Research Institute of the McGill University Health Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of mean glucose levels between artificial pancreas (AP) with empagliflozin with no-meal announcement meal approach strategy and AP without empagliflozin with carb-counting meal approach strategy.	Non-inferiority comparison of mean 14-hour glucose level obtained by continuous glucose monitoring between i) the AP with empagliflozin with no meal-announcement and ii) the AP with quantitative carbohydrate-counting without empagliflozin.	After completing 5 meal interventions (3-9 weeks)
Primary	Comparison of mean glucose levels between AP with empagliflozin with simple meal announcement strategy and AP without empagliflozin with carb-counting.	If there is a significant difference in the previous non-inferiority comparison, the following conditional primary comparison will be conducted: Non-inferiority comparison of mean 14-hour sensor glucose level obtained by continuous glucose monitoring between i) the AP with empagliflozin with simple meal-announcement and ii) the AP with quantitative carbohydrate-counting without empagliflozin.	After completing 5 meal interventions (3-9 weeks)
Secondary	Time spent in hypoglycemia	Percentage of time spent in the following glucose sensor levels: Between 3.9 and 10.0 mmol/l; Between 3.9 and 7.8 mmol/l; Above 7.8 mmol/l; Above 10.0 mmol/l; Above 13.9 mmol/l; Below 3.9 mmol/l; Below 3.3 mmol/l; Below 2.8 mmol/l.	After completing 5 meal interventions (3-9 weeks)
Secondary	Number of hypoglycemic events below 3.3 mmol/L	Number of hypoglycemic events (> 20 minutes) below 3.3 mmol/L based on continuous glucose monitoring sensor glucose level values.	After completing 5 meal interventions (3-9 weeks)
Secondary	Number of clinically remarkable hypoglycemic events	Number of symptomatic hypoglycemic events below 4.0 mmol/l or below 3.5 mmol/l without symptoms.	After completing 5 meal interventions (3-9 weeks)
Secondary	Number of treated hypoglycemic events	Number of hypoglycemic events or events perceived as hypoglycemia which prompt treatment by glucose or glucagon or overriding AP insulin dosing algorithm suggestion or by administering the regular meal earlier than planned.	After completing 5 meal interventions (3-9 weeks)
Secondary	Mean continuous glucose monitoring (CGM) glucose level	Comparison of mean CGM glucose levels between different meal interventions on and off empagliflozin.	After completing 5 meal interventions (3-9 weeks)
Secondary	Standard deviation of glucose levels	Comparison of values obtained from CGM on different meal intervention days.	After completing 5 meal interventions (3-9 weeks)
Secondary	Coefficient of variation of glucose levels	Comparison of values obtained from CGM on different meal intervention days.	After completing 5 meal interventions (3-9 weeks)
Secondary	Total insulin delivery	Comparison of total insulin delivered by AP on different meal intervention days.	After completing 5 meal interventions (3-9 weeks)
Secondary	Morning capillary ketone concentration	Safety outcome to assess risk of Empagliflozin related most serious side effect-diabetic ketoacidosis. Evaluated will be all days of study participation (i.e.not only meal intervention days)	After completing 5 meal interventions (3-9 weeks)